Patents by Inventor Dongyao YAN

Dongyao YAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UCK2 Assay To Predict Cancer Therapy Response
    Publication number: 20200271653
    Abstract: A method is provided for quantifying the UCK2 protein in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry and utilizing said quantitation of UCK2 to predict the therapeutic outcome of treating a colon cancer patient with the combinatorial FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin) treatment regimen.
    Type: Application
    Filed: September 20, 2018
    Publication date: August 27, 2020
    Inventors: Dongyao YAN, Fabiola CECCHI, Todd HEMBROUGH
  • OPRT expression and cancer treatment outcome
    Patent number: 10722531
    Abstract: Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable manner to a therapeutic strategy comprising the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) or a combination of capecitabine and cisplatin. Diagnostic methods for measuring the OPRT, TYMP, and/or UCK2 proteins in a tissue sample, such as a tumor sample, from the patient are provided.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Quantifying MGMT protein for optimal cancer therapy of glioblastoma
    Patent number: 10725045
    Abstract: Methods are provided for treating a cancer patient suffering from a glioblastoma (GBM) by administering to the patient an effective amount of temozolomide, wherein a mass spectrometry analysis of a protein digest of a formalin-fixed tumor sample from the patient evidences an amount of a MGMT fragment peptide less than or substantially equal to 150 amol/?g.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • Quantifying MGMT Protein For Optimal Cancer Therapy Of Glioblastoma
    Publication number: 20190265242
    Abstract: Methods are provided for treating a cancer patient suffering from a glioblastoma (GBM) by administering to the patient an effective amount of temozolomide, wherein a mass spectrometry analysis of a protein digest of a formalin-fixed tumor sample from the patient evidences an amount of a MGMT fragment peptide less than or substantially equal to 150 amol/?g.
    Type: Application
    Filed: February 12, 2019
    Publication date: August 29, 2019
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • OPRT Expression And Cancer Treatment Outcome
    Publication number: 20190262369
    Abstract: Improved methods for treating cancer are provided herein by determining if a cancer patient, particularly a colon cancer patient or a gastric cancer patient, will clinically respond in a favorable manner to a therapeutic strategy comprising the FOLFOX regimen (fluorouracil, leucovorin, and oxaliplatin) or a combination of capecitabine and cisplatin. Diagnostic methods for measuring the OPRT, TYMP, and/or UCK2 proteins in a tissue sample, such as a tumor sample, from the patient are provided.
    Type: Application
    Filed: February 12, 2019
    Publication date: August 29, 2019
    Inventors: Todd A. Hembrough, Fabiola Cecchi, Dongyao Yan
  • METHODS FOR TREATING SARCOMA
    Publication number: 20190167628
    Abstract: Molecular markers of response to various chemotherapies were measured in tumor samples of 5 sarcoma subtypes to identify effective treatment regimens based on expression of chemotherapy biomarkers. The molecular profiles for rhabdomyosarcoma support the use of standard-of-care treatment, while other profiles showed that alternative agents differing from standard-of-care will be effective, including gemcitabine (osteosarcoma), taxane (leiomyosarcoma, Ewing's sarcoma), and platinum (leiomyosarcoma, liposarcoma, and osteosarcoma).
    Type: Application
    Filed: December 3, 2018
    Publication date: June 6, 2019
    Inventors: Sheeno THYPARAMBIL, Dongyao YAN, Shankar SELLAPPAN, Fabiola CECCHI, Todd HEMBROUGH, Yeoun Jin KIM, Andrew CHAMBERS